myTomorrows Raises $29 Million From Avego to Scale AI Platform for Pre-Approval Treatments
The Avego investment positions the Amsterdam company to expand its AI platform for earlier patient access to investigational therapies.
Overview
- myTomorrows closed a $29 million financing from Avego to accelerate growth of its global access platform, the company announced.
- The funding will support international expansion, faster AI development, deeper collaborations with BioPharma partners, and stronger real‑world evidence and regulatory insight capabilities.
- The AI-enabled platform connects patients, physicians, clinical trial sites, and drugmakers to match and secure access to clinical trials and expanded access programs.
- The company reports it has supported more than 16,900 patients with services spanning trial recruitment, expanded access management, referral tools for sites, and real‑world data collection across 133+ countries.
- Tech Funding News reports the platform integrates with electronic health records and claims GDPR and HIPAA compliance for data protection, as stated by the company.